Karachi (March 24, 2026): AGP Limited, a prominent player in Pakistan’s pharmaceutical sector, has formally notified the Pakistan Stock Exchange (PSX) of its board’s decision to pursue a share buy-back programme. The announcement, dated today, follows a board meeting held on March 19, 2026, at 2:00 p.m.
In line with Sections 96 and 131 of the Securities Act, 2015, and relevant provisions of the Companies Act, 2017, along with the Listed Companies (Buy-Back of Shares) Regulations, 2019, the Board has approved and recommended to members the purchase of up to 5,600,000 (Five Million Six Hundred Thousand) issued ordinary shares. These shares represent approximately 2.0% of the company’s current issued and paid-up capital of 280 million shares (face value PKR 10 each).
The buy-back is subject to the approval of shareholders through special resolutions at a forthcoming general meeting and compliance with all regulatory requirements, including Section 88 of the Companies Act. The company has highlighted that the move aims to enhance shareholder value, optimize capital structure, and signal management’s confidence in the firm’s future prospects.
AGP Limited, listed on the PSX since 2018, is engaged in the import, marketing, manufacturing, and distribution of a wide range of pharmaceutical products. The company operates under the tagline “we value life” and maintains strong ties with international partners. Its majority shareholder is Aitkenstuart Pakistan (Private) Limited, which holds around 55.8% stake.
Market analysts view the proposed buy-back positively. With the stock recently trading around PKR 191–202 per share, the maximum programme could involve an outlay of roughly PKR 1.07–1.13 billion, depending on prevailing market prices. Such repurchases often support share prices by reducing the floating stock and improving earnings per share (EPS) for remaining shareholders.
The company has scheduled an Annual General Meeting (AGM) for April 20, 2026, where shareholders are expected to deliberate on the special resolutions for the buy-back. Once approved, the repurchase process is likely to commence shortly thereafter, in accordance with PSX rules and SECP guidelines.
This development comes at a time when AGP has been showing resilience in the pharmaceutical space, with analysts earlier in 2026 projecting upside potential in its valuation. The buy-back underscores the company’s commitment to efficient capital allocation and returning value to investors amid a dynamic economic environment.
Shareholders and market participants are advised to monitor further disclosures from the company and the PSX for updates on the exact timeline, pricing mechanism, and execution details of the buy-back.
